Replies to post #4960 on GTC Biotherapeutics (fka GTCB)

[keitern]

Flo, I was teeing off this:
From Sept. 4th. I believe:
>>Rodman & Renshaw notes that GTCB disclosed earlier today that the FDA has designated ATryn a "fast track product" entitled to accelerated FDA review for the antithrombin hereditary deficiency indication. The firm views the granting of the Fast Track Designation to ATryn for AT-HD as a positive development for GTCB. They are cognizant that A.T-H.D. is a very small indication in which GTCB is unlikely to derive significant commercial sales for ATryn. However, they say U.S. approval will provide a further validation of the co's transgenic goat protein-production technology and will allow the co to establish a strong foothold in the U.S. which would position ATryn well for much larger indications such as disseminated intravascular coagulation in association with severe sepsis, and burn. <<
Anyway, I called TN at GTC and discussed this with him and came away with the same feeling, that AT-HD is even smaller in the US than in the EU and would not fund the kind of growth GTC is looking for, however, it would generate profits and would be "worth doing" in it's own right, but the main reason for doing it would be the DIC ind. I understand the part about GTC not having to share the profit nearly as much as in the EU.
It would be helpful for investors to be able to get a range of sales and subsequent profit potential from the combined AT-HD programs. I bet that eventually cash flow would be near 10M annually at the top end, witch should yield a market cap over today's EV for that alone. I have to admit that I view AT-HD in the US as pretty much a given, barring some strange data coming back from usage in the EU.